Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 25, 2017

DrugPatentWatch Database Preview

Amlodipine besylate; atorvastatin calcium - Generic Drug Details

« Back to Dashboard

What are the generic sources for amlodipine besylate; atorvastatin calcium and what is the scope of amlodipine besylate; atorvastatin calcium patent protection?

Amlodipine besylate; atorvastatin calcium
is the generic ingredient in two branded drugs marketed by Pfizer, Mylan Pharms Inc, and Dr Reddys Labs Ltd, and is included in three NDAs. There are three patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Amlodipine besylate; atorvastatin calcium has one hundred and twenty-five patent family members in fifty-two countries.

There are forty-nine drug master file entries for amlodipine besylate; atorvastatin calcium. Six suppliers are listed for this compound.

Summary for Generic Name: amlodipine besylate; atorvastatin calcium

Drug Master File Entries: see list49
Suppliers / Packagers: see list6
Clinical Trials: see list1,084
Drug Prices:see low prices
DailyMed Link:amlodipine besylate; atorvastatin calcium at DailyMed

Pharmacology for Ingredient: amlodipine besylate; atorvastatin calcium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
amlodipine besylate; atorvastatin calcium
TABLET;ORAL021540-004Jan 30, 2004ABRXYesNo6,455,574► Subscribe ► Subscribe
amlodipine besylate; atorvastatin calcium
TABLET;ORAL021540-011Jul 29, 2004ABRXYesNo6,455,574► Subscribe ► Subscribe
Mylan Pharms Inc
amlodipine besylate; atorvastatin calcium
TABLET;ORAL200465-007Nov 29, 2013ABRXNoNo► Subscribe► Subscribe
Dr Reddys Labs Ltd
amlodipine besylate; atorvastatin calcium
TABLET;ORAL203874-005Mar 7, 2014ABRXNoNo► Subscribe► Subscribe
Dr Reddys Labs Ltd
amlodipine besylate; atorvastatin calcium
TABLET;ORAL203874-011Mar 7, 2014ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Uncover prior art in abandoned patent applications and expired patents
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus